Trial Profile
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Levetiracetam (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 19 Oct 2023 Planned End Date changed from 30 Sep 2023 to 30 Jun 2024.
- 19 Oct 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Jun 2024.
- 19 Oct 2023 Status changed from recruiting to active, no longer recruiting.